Grant McArthur

The Development and Piloting of a Virtual Reality Patient Consultation Simulation to Improve Oncology Practitioners Communication and Counseling Skills

David L Kok, Daniel Sapkaroski, Sathana Dushyanthen, Justine Diggens, Nigel Anderson, Michelle Barrett, Grant McArthur

Conference Proceedings  |  2021  |  International Journal of Radiation Oncology*Biology*Physics

Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.

Marie-Luise Hilbers, Florentia Dimitriou, Peter Lau, Prachi Bhave, Grant A McArthur, Lisa Zimmer, Ken Kudura, Camille L Gérard, Mitchell P Levesque, Olivier Michielin, Reinhard Dummer, Phil F Cheng, Joanna Mangana

Journal article  |  2021  |  Eur J Cancer

BACKGROUND: Melanoma brain metastases (MBM) have a poor prognosis. Systemic treatments that have improved outcomes in advanced mel..

Is resistance to targeted therapy in cancer inevitable?

Lorey K Smith, Karen E Sheppard, Grant A McArthur

Journal article  |  2021  |  CANCER CELL

Resistance to targeted therapies is a major challenge in cancer care and occurs via genetic and non-genetic mechanisms. In this is..

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.

Paolo A Ascierto, Brigitte Dréno, James Larkin, Antoni Ribas, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Jessie Hsu, Surai Jones, Haocheng Li, Edward McKenna, Athina Voulgari, Grant A McArthur

Journal article  |  2021  |  Clin Cancer Res

PURPOSE: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall sur..

Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi

Susan J Robertson, Lisa Orme, Rodrigo Teixeira, Maryam Shamassi, Felicity Newell, Ann-Marie Patch, Iwei Yeh, Grace Gard, James Wilmott, Louise Jackett, Philip LeBoit, Andrew Fellowes, Grant MacArthur, Stephen Fox, Nicholas K Hayward, Boris Bastian, Richard Scolyer, Nicola Waddell, Anthony Penington, Mark Shackleton

Journal article  |  2021  |  JAMA DERMATOLOGY

Importance: Spitz nevi are benign melanocytic neoplasms that classically present in childhood. Isolated Spitz nevi have been assoc..

gamma delta T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival

Nicholas A Gherardin, Kelly Waldeck, Alex Caneborg, Luciano G Martelotto, Shiva Balachander, Magnus Zethoven, Pasquale M Petrone, Andrew Pattison, James S Wilmott, Sergio M Quinones-Parra, Fernando Rossello, Atara Posner, Annie Wong, Alison M Weppler, Kerwin F Shannon, Angela Hong, Peter M Ferguson, Valerie Jakrot, Jeanette Raleigh, Athena Hatzimihalis, et al.

Journal article  |  2021  |  CANCER IMMUNOLOGY RESEARCH

Merkel cell carcinomas (MCC) are immunogenic skin cancers associated with viral infection or UV mutagenesis. To study T-cell infil..

Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).

Georgina V Long, Victoria Atkinson, Serigne Lo, Alexander David Guminski, Shahneen Kaur Sandhu, Michael Paul Brown, Maria Gonzalez, Richard A Scolyer, Louise Emmett, Grant A McArthur, Alexander M Menzies

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

9508 Background: Preliminary data from the ABC (76 pts) and CheckMate 204 (94 pts) trials showed that nivo and nivo+ipi have acti..

Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation–positive advanced melanoma.

Caroline Robert, Karl D Lewis, Paolo Antonio Ascierto, Rodrigo Ramella Munhoz, Gabriella Liszkay, Luis de la Cruz-Merino, Judit Olah, Paola Queirolo, Jacek Mackiewicz, Ivor Caro, Kalpit Shah, Harper Forbes, Haocheng Li, Christian Hertig, Yibing Yan, Edward Francis Mckenna, Ralf Gutzmer, Grant A McArthur

Journal article  |  2021  |  Journal of Clinical Oncology

9523 Background: The phase 3 IMspire150 study showed that first-line A+V+C improved investigator-assessed PFS vs placebo (P)+V+C ..

CDK4/6 inhibition promotes anti-tumor immunity through the induction of T cell memory.

Emily J Lelliott, Isabella Y Kong, Magnus Zethoven, Kelly M Ramsbottom, Luciano G Martelotto, Deborah Meyran, Joe Jiang Zhu, Matteo Costacurta, Laura Kirby, Jarrod J Sandow, Lydia Lim, Pilar M Dominguez, Izabela Todorovski, Nicole M Haynes, Paul A Beavis, Paul J Neeson, Edwin D Hawkins, Grant A McArthur, Ian A Parish, Ricky W Johnstone, et al.

Journal article  |  2021  |  Cancer Discov

Pharmacological inhibitors of cyclin dependent kinases 4 and 6 (CDK4/6) are an approved treatment for hormone receptor-positive br..

Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma

Emily J Lelliott, Grant A McArthur, Jane Oliaro, Karen E Sheppard

Journal article  |  2021  |  FRONTIERS IN IMMUNOLOGY

The recent advent of targeted and immune-based therapies has revolutionized the treatment of melanoma and transformed outcomes for..